Compare · BSX vs NVCR
BSX vs NVCR
Side-by-side comparison of Boston Scientific Corporation (BSX) and NovoCure Limited (NVCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NVCR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 35.5x NVCR ($1.84B).
- Over the past year, BSX is down 57.5% and NVCR is down 0.6% - NVCR leads by 56.9 points.
- NVCR has been more active in the news (8 items in the past 4 weeks vs 2 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- NovoCure Limited
- Price
- $44.02-1.32%
- $15.91-3.14%
- Market cap
- $65.44B
- $1.84B
- 1M return
- -6.16%
- -8.93%
- 1Y return
- -57.53%
- -0.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 2
- 8
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest NVCR
- Analyst resumed coverage on NovoCure with a new price target
- Chief Human Resources Officer Puri Michal Nath was granted 1,905 units of Ordinary Shares, increasing direct ownership by 0.95% to 203,227 units (SEC Form 4)
- Chief Executive Officer Leonard Frank X was granted 1,905 units of Ordinary Shares, increasing direct ownership by 0.41% to 461,425 units (SEC Form 4)
- General Counsel Ben Arye Barak was granted 1,299 units of Ordinary Shares, increasing direct ownership by 0.54% to 243,752 units (SEC Form 4)
- Director Danziger Asaf was granted 268 units of Ordinary Shares, increasing direct ownership by 0.06% to 416,742 units (SEC Form 4)
- Novocure to Report Second Quarter 2026 Financial Results
- NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
- NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma